Suppr超能文献

通过液体活检区分肺磨玻璃结节良恶性的生物标志物

Biomarkers via liquid biopsy for distinguishing malignant from benign pulmonary ground-glass nodule.

作者信息

Wu Zhen, Liang Yuan, Li Chun Sun, Guo Hua, Yang Zhen, Zhao Wei, Chen Liang An

机构信息

Department of Respiratory, First Medical Center of Chinese PLA General Hospital, Beijing, China.

出版信息

iScience. 2025 Jul 16;28(9):113128. doi: 10.1016/j.isci.2025.113128. eCollection 2025 Sep 19.

Abstract

The differentiation between benign and malignant pulmonary ground-glass nodules (GGNs) has always been a current clinical hotspot issue. Patients with pulmonary GGNs from 8 centers were enrolled to identify biomarkers for malignancy and benignity discrimination, and an integrated biomarker panel comprising two miRNA, one long non-coding RNA (lncRNA), and one circular RNA (cirRNA) identified by multivariate logistic regression analysis were established. The classifier had area under the receiver-operating characteristic (ROC) curve (AUC) of 0.88, 87.8% sensitivity and 70% specificity, being significantly higher compared with the Mayo model (AUC of 0.72), Brock model (AUC of 0.70), and Herder model (AUC of 0.82) (all < 0.05). Moreover, relative expression of and gradually increased from adenocarcinoma (AIS) to minimally invasive adenocarcinoma (MIA) to invasive adenocarcinoma (IAC). The classifier was validated in two independent sets of patients. It has been proved that the integration of three kinds of non-coding RNAs (ncRNAs) could more accurately identify early staged lung cancer among indeterminate GGNs.

摘要

肺磨玻璃结节(GGN)的良恶性鉴别一直是当前临床热点问题。来自8个中心的肺GGN患者被纳入研究,以确定用于鉴别恶性和良性的生物标志物,并建立了一个由多因素逻辑回归分析确定的包含两种微小RNA(miRNA)、一种长链非编码RNA(lncRNA)和一种环状RNA(cirRNA)的综合生物标志物组。该分类器的受试者操作特征曲线(ROC)下面积(AUC)为0.88,灵敏度为87.8%,特异性为70%,与梅奥模型(AUC为0.72)、布罗克模型(AUC为0.70)和赫德模型(AUC为0.82)相比显著更高(均P<0.05)。此外,[具体指标]的相对表达从原位腺癌(AIS)到微浸润腺癌(MIA)再到浸润性腺癌(IAC)逐渐升高。该分类器在两组独立患者中得到验证。已证明三种非编码RNA(ncRNA)的整合能够更准确地在不确定的GGN中识别早期肺癌。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb7/12357096/09e9d11d442f/fx1.jpg

相似文献

1
Biomarkers via liquid biopsy for distinguishing malignant from benign pulmonary ground-glass nodule.
iScience. 2025 Jul 16;28(9):113128. doi: 10.1016/j.isci.2025.113128. eCollection 2025 Sep 19.
2
Comparison of the Brock model and LU-RADS in differentiating benign and malignant sub-solid pulmonary nodules.
Indian J Cancer. 2025 Apr 1;62(2):184-189. doi: 10.4103/ijc.ijc_397_22. Epub 2025 Aug 8.
3
The Value of Topological Radiomics Analysis in Predicting Malignant Risk of Pulmonary Ground-Glass Nodules: A Multi-Center Study.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241287089. doi: 10.1177/15330338241287089.
4
Assessment of extracellular vesicle microRNAs detection in predicting benign and malignant pulmonary ground glass nodules.
Front Med (Lausanne). 2025 Jun 25;12:1600429. doi: 10.3389/fmed.2025.1600429. eCollection 2025.
6
A Nomogram Combining Two Novel Biomarkers for Predicting Lung Adenocarcinoma in Ground-Glass Nodule Patients.
Hum Mutat. 2025 Jun 11;2025:8647969. doi: 10.1155/humu/8647969. eCollection 2025.
8
Natural course of lung adenocarcinoma manifesting as ground-glass nodules: invasiveness assessment based on growth evaluation.
Transl Lung Cancer Res. 2025 Jun 30;14(6):2180-2196. doi: 10.21037/tlcr-2025-395. Epub 2025 Jun 24.
10
Radiomic 'Stress Test': exploration of a deep learning radiomic model in a high-risk prospective lung nodule cohort.
BMJ Open Respir Res. 2025 Jun 27;12(1):e002687. doi: 10.1136/bmjresp-2024-002687.

本文引用的文献

2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
Integrative Omics Analysis Reveals Metabolic Features of Ground-Glass Opacity-Associated Lung Cancer.
J Cancer. 2024 Feb 4;15(7):1848-1862. doi: 10.7150/jca.92437. eCollection 2024.
4
Genetic characteristics of lung adenocarcinoma with ground-glass opacity component.
J Thorac Dis. 2023 Nov 30;15(11):6106-6114. doi: 10.21037/jtd-23-745. Epub 2023 Nov 14.
5
Incidental pulmonary nodules - current guidelines and management.
Rofo. 2024 Jun;196(6):582-590. doi: 10.1055/a-2185-8714. Epub 2023 Dec 8.
6
miRNA as biomarker in lung cancer.
Mol Biol Rep. 2023 Nov;50(11):9521-9527. doi: 10.1007/s11033-023-08695-9. Epub 2023 Sep 23.
8
Non-coding RNA-directed therapeutics in lung cancer: Delivery technologies and clinical applications.
Colloids Surf B Biointerfaces. 2023 Sep;229:113466. doi: 10.1016/j.colsurfb.2023.113466. Epub 2023 Jul 18.
9
Differences of molecular events driving pathological and radiological progression of lung adenocarcinoma.
EBioMedicine. 2023 Aug;94:104728. doi: 10.1016/j.ebiom.2023.104728. Epub 2023 Jul 26.
10
Early Detection of Lung Cancer Using Small RNAs.
J Thorac Oncol. 2023 Nov;18(11):1504-1523. doi: 10.1016/j.jtho.2023.07.005. Epub 2023 Jul 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验